Posted on

cbd oil cortisol

According to the findings of a study conducted back in 1993, CBD was found to interfere with the production of cortisol . As such, CBD might act as an anti-catabolic. An anti-catabolic compound helps prevent the breakdown of muscle mass within the body. Prolonged levels of cortisol in the blood might be linked to a loss of tissue proteins. This means that CBD may help eliminate the negative effects of high cortisol levels in the body by reducing the production of the hormone.

With the help of CBD, you may experience improved sleep at night, after a stressful day. As previously mentioned, cortisol levels in the blood naturally spike in the morning and reduce significantly at night. However, for those suffering from chronic high levels, going to sleep can be quite a challenge. This is because their body is in a constant state of fight or flight.

When the body experiences stress, it increases the chance for oxidative damage. This means that the amount of free radicals throughout the body might be increased. These free radicals are known for causing tissue damage. CBD’s potential antioxidant properties may help to combat and protect the body from these tissue-damaging free radicals .

Antioxidant Properties

It is important to note that cortisol levels in the body vary over the course of the day; spiking in the morning when we need to bounce out of bed and decrease as evening approaches. A cortisol test conducted by a medical professional can help you ascertain whether you have high, normal, or low levels of the hormone.

CBD is an anti-catabolic that may help regulate the production of cortisol through its interaction with the endocannabinoid system. This regulation might help to ensure that normal levels are maintained in the blood. If you want to get the best results from CBD use, it is recommended that you look for high-quality CBD products.

As previously mentioned, normal cortisol levels help boost your health. Overall, maintaining normal levels of this hormone is essential in facilitating the normal functioning of the body.

In women who are going through the stress and anxiety caused by hormonal changes resulting from high cortisol levels, CBD may be able to help. With the help of this natural compound, you may experience improved sleep and/or weight management issues. These issues are normally associated with large fluctuations in cortisol levels in the blood.

Although lower than in healthy controls, baseline prolactin levels in frequent users were within the normal physiological range for prolactin. Whether the lower prolactin levels in this study were clinically significant was not evaluated.

Cortisol and prolactin levels were measured at baseline (i.e., before) and 70 min after administration of i.v. Δ-9-THC. Plasma cortisol was measured by radioimmunoassay after denaturation of the binding proteins by heat. Primary antibodies (raised in rabbit against cortisol-3-0-carboxymethyloxime-BSA) and I 125 -labeled cortisol were purchased from ICN Biomedicals. The cortisol standard was purchased from Sigma Chemical. Antirabbit globulin serum in conjunction with polyethylene glycol was used for separation of the bound and free fractions. Samples were assayed in duplicate. Plasma prolactin was measured by a double antibody radioimmunoassay. The prolactin standard was purchased from Calbiochem and was calibrated against the National Pituitary Agency (NPA) primary prolactin standard (HPRL-RP-1). The antiserum was donated by the NPA. The labeled PRL-1 125 was purchased from New England Nuclear and repurified on the day of the assay on a G-100 Sephadex column. Antirabbit globulin serum was used for separation of bound and free fractions. Samples were assayed in duplicate.

After obtaining written informed consent, subjects (18–55 years) underwent a structured psychiatric interview for DSM-IIIR or DSM-IV (First et al. 2002) and were carefully screened for any DSM axis I or axis II lifetime psychiatric or substance use disorder (except for cannabis in the case of frequent users) and family history of major axis I disorder. All subjects were asked to estimate their lifetime cannabis exposure (number of times), heaviest exposure, and last exposure to cannabis. Subjects were excluded for recent abuse (3 months) or dependence (1 year) to alcohol or any substances other than nicotine in both groups and cannabis in the frequent user group. Cannabis-naïve individuals were excluded to minimize any risk of promoting future cannabis use/abuse. The history provided by subjects was confirmed by a telephone interview conducted with an individual (spouse or family member) identified by the subject prior to screening. A general physical and neurological examination, electrocardiogram, and laboratory tests (serum electrolytes, liver function tests, complete blood count with differential and urine toxicology) were also conducted. Both groups were instructed to refrain from alcohol, illicit drugs, or prescription drugs not approved by the research team for 2 weeks before the study and throughout study participation. Frequent users were permitted to use cannabis until 24 h prior to each test day to minimize cannabis withdrawal effects.

Lower baseline and post-Δ-9-THC prolactin levels in frequent users

Several issues should be considered in interpreting the results. First, blood was not sampled at exactly the same time points across the two studies. Second, basal (early morning) cortisol levels were not sampled. However, these studies were not aimed primarily at evaluating basal HPA axis activity. Rather, these studies were aimed at evaluating HPA axis responsivity to the administration of cannabinoids. This was reflected in the change in cortisol levels (pre–post Δ-9-THC administration). In order to address the interindividual and intra-individual variability and because study II cortisol levels were assayed later in the day, analyses were covaried for baseline cortisol levels. Furthermore, the sample consisted of both men and women; the small number of women in the sample was insufficient to determine if gender had significantly affected the hormonal levels. Three subjects in each group were on oral contraceptive medications which could have affected their prolactin response.

Preclinical studies suggest that the acute administration of delta-9-tetrahydrocannabinol (Δ-9-THC), the principal active constituent of cannabis, is associated with a dose-dependant increase in cortisol levels (Brown and Dobs 2002). However, in humans, the acute effects of cannabinoids on cortisol release are less clear with some (Cone et al. 1986), but not other studies (Dax et al. 1989) reporting increased cortisol levels associated with acute administration of cannabinoids.

In summary, the existing literature, while suggestive of an acute effect of cannabinoids on cortisol and prolactin release in humans, is limited by small sample sizes (n=6–22), heterogeneous samples with regard to cannabis exposure, lack of controlling for chronic cannabis exposure, differing methodologies, and limited dose–response data. Related to dose–response, some cannabinoid effects, e.g., on anxiety are biphasic, with low and high doses producing divergent effects. Whether cannabinoids have biphasic hormonal effects in humans is unknown. Finally, while there are some studies that have separately examined the acute and chronic endocrine effects of cannabinoids in humans, we are unaware of any studies comparing the acute, chronic, and acute on chronic effects. Chronic and acute on chronic effects of Δ-9-THC on endocrine function may reflect clinically relevant evidence of long-term adaptation of the cannabinoid receptor system associated with chronic cannabis use.

The human and preclinical literature is mixed with reports of a decrease, increase, or no change in prolactin levels following the administration of cannabinoids (Cone et al. 1986; Dax et al. 1989; Lemberger et al. 1975; Markianos and Stefanis 1982; Mendelson et al. 1984; Mendelson et al. 1985; Murphy et al. 1990; Rettori et al. 1988; Wenger et al. 1987).